...
首页> 外文期刊>Epigenetics: official journal of the DNA Methylation Society >The epigenetic regulation of Dicer and microRNA biogenesis by Panobinostat
【24h】

The epigenetic regulation of Dicer and microRNA biogenesis by Panobinostat

机译:Panobinostat的Dicer和MicroRNA生物发生的表观遗传调节

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

microRNAs (miRs) are small noncoding RNAs that regulate/fine tune many cellular protein networks by targeting mRNAs for either degradation or translational inhibition. Dicer, a type III endoribonuclease, is a critical component in miR biogenesis and is required for mature microRNA production. Abnormal Dicer expression occurs in numerous cancer types and correlates with poor patient prognosis. Recent reports have demonstrated that epigenetic agents, including histone deacetylase inhibitors (HDACi), may regulate Dicer and miR expression. HDACi are a class of epigenetic agents used to treat cancer, viral infections, and inflammatory disorders. However, little is known regarding the epigenetic regulation of miR biogenesis and function. We therefore investigated whether clinically successful HDACi modulated Dicer expression and found that Panobinostat, a clinically approved HDACi, enhanced Dicer expression via posttranscriptional mechanisms. Studies using proteasome inhibitors suggested that Panobinostat regulated the proteasomal degradation of Dicer. Further studies demonstrated that Panobinostat, despite increasing Dicer protein expression, decreased Dicer activity. This suggests that Dicer protein levels do not necessarily correlate with Dicer activity and mature miR levels. Taken together, we present evidence here that Panobinostat posttranscriptionally regulates Dicer/miR biogenesis and suggest Dicer as a potential therapeutic target in cancer.
机译:MicroRNAS(MIRS)是小型非编码RNA,其通过针对劣化或翻译抑制来调节/微调许多细胞蛋白网络。 Dicer,一种III型内衣核酸酶,是MIR生物发生的关键组分,并且是成熟的MicroRNA生产所必需的。异常的Dicer表达发生在许多癌症类型中,与患者预后差相关。最近的报道已经证明,表观遗传症,包括组蛋白脱乙酰酶抑制剂(HDACI),可调节DICER和MIR表达。 HDACI是一种用于治疗癌症,病毒感染和炎症性疾病的一类表观遗传因子。然而,关于miR生物发生和功能的表观遗传调节很少。因此,我们研究了临床上成功的HDACI调节的DICER表达,发现PANOBINOSTAT,临床批准的HDACI,通过后术式机制增强了DICER表达。使用蛋白酶体抑制剂的研究表明Panobinostat调节了Dicer的蛋白酶体降解。进一步的研究表明,尽管提高了Dicer蛋白表达,但Panobinostat仍降低了Dicer活性。这表明Dicer蛋白水平不一定与Dicer活性和成熟的MiR水平相关。我们一起服用,这里有证据表明Panobinostat后发出调节Dicer / miR生物发生,并提示Dicer作为癌症中的潜在治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号